How to alleviate the side effects of Ripotinib

Repotrectinib is suitable for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Although it has significant efficacy, it may cause a variety of adverse reactions during clinical use. Understanding the performance characteristics of these side effects, scientific mitigation methods, and correct medication practices are crucial to improving patients' treatment compliance and quality of life.

Side effects of Ripotinib

may cause multi-system adverse reactions during clinical application. The following are side effects that have a high incidence and require special attention.

Nervous system adverse reactions

Most patients may experience central nervous system symptoms such as dizziness, ataxia, and cognitive impairment. These symptoms usually appear in the early stages of medication and may affect patients' daily activities and quality of life.

Respiratory system toxicity

Some patients will develop interstitial lung disease/pneumonitis, manifesting as new or worsening symptoms such as dyspnea and dry cough. Severe cases require immediate medical intervention.

Abnormal liver function

Patients with elevated transaminases are usually asymptomatic, but may progress to drug-induced liver injury, and require regular monitoring of ALT, AST and other indicators.

After recognizing the manifestations of these side effects, taking targeted mitigation measures can help patients better tolerate treatment.

How to alleviate the side effects of Ripotinib

To address the different adverse reactions of Ripotinib, the following scientific and effective mitigation strategies can be adopted.

Management of Nervous System Symptoms

When dizziness or ataxia occurs, patients are advised to slowly change their position and avoid driving or operating precision instruments. Mild cognitive impairment can be improved through cognitive training. In severe cases, short-term reduction or suspension of medication may be considered.

Response to respiratory complications

Once interstitial lung disease is suspected, medication should be stopped immediately and chest CT examination should be completed. Glucocorticoid treatment can be considered after diagnosis. After symptoms are completely relieved, it is prudent to evaluate whether to restart treatment.

Measures to protect liver function

Intensify monitoring when transaminases are mildly elevated. If the transaminase is moderately elevated, medication should be suspended and supplemented with hepatoprotective treatment. After recovery, you can consider reducing the dosage and continuing treatment, while avoiding the concomitant use of other hepatotoxic drugs.

While mastering the methods to alleviate side effects, following standardized medication guidelines is the basis for ensuring the safety of treatment.

Repretinib Medication Guide

The correct use of repotinib requires strict compliance with the following medication principles and monitoring requirements, and strict compliance with physician instructions.

Standard dosage regimen

The starting dose is 160 mg orally once a day, increasing to 160 mg twice a day after 14 days. The tablet should be swallowed whole and should not be affected by eating. If you miss a dose, do not make up for it and continue with the next dose as originally planned.

Treatment monitoring specifications

Liver function, CPK and uric acid should be monitored every 2 weeks in the first month of treatment, and once a month thereafter. Check at any time when symptoms such as myalgia and dyspnea occur. Women of childbearing age need monthly pregnancy tests.

Adjustment for special groups

Patients with moderate to severe liver damage should use it with caution. Breastfeeding should be suspended during lactation. Non-hormonal contraceptive measures must be taken during use, as the drug may affect the effectiveness of hormonal contraception.

Reputinib brings new treatment hope to patients with ROS1-positive lung cancer. Patients should reasonably deal with side effects and standardize medication. Patients should use it under the guidance of professional physicians and maintain regular follow-up monitoring.